KR100972773B1 - 제산 ·완하용 정제 - Google Patents
제산 ·완하용 정제 Download PDFInfo
- Publication number
- KR100972773B1 KR100972773B1 KR1020037003649A KR20037003649A KR100972773B1 KR 100972773 B1 KR100972773 B1 KR 100972773B1 KR 1020037003649 A KR1020037003649 A KR 1020037003649A KR 20037003649 A KR20037003649 A KR 20037003649A KR 100972773 B1 KR100972773 B1 KR 100972773B1
- Authority
- KR
- South Korea
- Prior art keywords
- tablet
- magnesium oxide
- oxide particles
- weight
- tableting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
본 발명은 위산 과다 혹은 위산 분비 항진증 또는 변비에 사용되는 제산 ·완하용 정제에 관한 것으로서, 보다 상세하게는 타정 장해, 정제의 거무스름함 및 타정 얼룩이 실질적으로 존재하지 않고, 산화 마그네슘 입자의 함유 비율이 높으면서 물과 함께 복용하면 입 안에서 빠르게 붕괴되기 때문에 복용하기 쉬운 산화 마그네슘 입자 함유 정제에 관한 것이다. 더욱 상세하게는, 정제중의 산화 마그네슘 입자의 함유량이 88 중량% 이상이고, 동시에 붕괴 시간이 10 초 이하인 제산 ·완하용 산화 마그네슘 입자 함유 정제에 관한 것이다.
| 실시예 1 | 실시예 2 | 실시예 3 | 실시예 4 | 비교예 1 | ||
| 1 정제 중량 (㎎) | 375 | 360 | 285 | 375 | 367 | |
| 정제 경도 (N) | >70 | >110 | >70 | >60 | >40 | |
| 붕괴 시간 (초) | 7 | <7 | 6 | 8 | 20 | |
| 마손도 (%) | <0.3 | <0.3 | <0.1 | <0.5 | 0.8 | |
| 마모성 | 거무스름함 | 없음 | 없음 | 없음 | 없음 | 있음 |
| 타정 얼룩 | 없음 | 없음 | 없음 | 없음 | 있음 | |
| 제제의 안정성 | ||||
| 실시예 1 | 실시예 3 | 비교예 1 | ||
| 붕괴 시간 (초) |
가속 시험 전 | 7 | 6 | 20 |
| 2 개월째 | 7 | 7 | 455 | |
| 4 개월째 | 9 | 8 | 1024 | |
| 6 개월째 | 8 | 8 | >1800 | |
| 입 안에서의 붕괴성 | ||
| 사람수 | ||
| 실시예 1 | 실시예 3 | |
| 6 초 | 0 | 3 |
| 7 초 | 1 | 4 |
| 8 초 | 6 | 5 |
| 9 초 | 5 | 0 |
| 용출 시험 | ||
| 용출율 (%) | ||
| 시간 (분) | 실시예 1 | 실시예 3 |
| 5 | 34.8 | 33.0 |
| 10 | 57.1 | 80.1 |
| 15 | 85.5 | 92.0 |
| 30 | 101.1 | 103.9 |
| 45 | 111.0 | 104.0 |
| 60 | 108.6 | 103.5 |
| 군 | 투여 용량 (㎎/mL) | 투여액량 (mL/㎏) | 마릿수 |
| 대조 (0.5 % CMC) | - | 10 | 10 |
| 실시예 1 | 250 | 10 | 10 |
| 실시예 2 | 250 | 10 | 10 |
| 완하 작용의 동물 시험 | |||||||||||||
| 연한 변 내지 설사 발현 개체수 | |||||||||||||
| 시간 | |||||||||||||
| 군 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 24 |
| 대조군 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 실시예 1 | 4 | 6 | 9 | 9 | 10 | 8 | 5 | 3 | 1 | 0 | 0 | 0 | 0 |
| 실시예 3 | 4 | 6 | 9 | 10 | 10 | 8 | 4 | 2 | 1 | 0 | 0 | 0 | 0 |
Claims (14)
- 산화 마그네슘 입자를 유효 성분으로 하는 정제로서, 상기 정제는(i) 그 중에 함유되는 산화 마그네슘 입자는 레이저 회절 산란법으로 측정된 평균 2 차 입자경이 0.5 내지 10 ㎛ 이고,(ii) 그 중에 함유되는 산화 마그네슘 입자의 함유 비율이 88 중량% 내지 97 중량% 이며,(iii) 거무스름함 및 타정 얼룩이 발견되지 않고,(iv) 붕괴 시간이 10 초 이하이며,(v) 산화 마그네슘 입자는 레이저 회절 산란법으로 측정된 평균 2 차 입자경이 1 내지 10 ㎛ 인 수산화 마그네슘 입자를 700 내지 1000 ℃ 의 온도에서 소성하여 얻어지고,(vi) 정제는 결합제로서 결정 셀룰로오스 또는 전분을 1 내지 10 중량% 함유하며,(vii) 정제는 붕괴제로서 크로스카르멜로오스나트륨, 카르멜로오스칼슘 및 카르복시스타치나트륨으로 이루어지는 군에서 선택되는 1 종 이상을 1 내지 3.5 중량% 함유하고,(viii) 정제는 평균 입자경이 0.25 내지 0.40 ㎜ 인 과립형 산화 마그네슘 입자로 형성되며,(xi) 정제는 안식각이 35 내지 43 °인 과립형 산화 마그네슘 입자로 형성되는 것을 특징으로 하는 제산 ·완하용 정제.
- 제 1 항에 있어서, 상기 산화 마그네슘 입자는 레이저 회절 산란법으로 측정된 평균 2 차 입자경이 1 내지 7 ㎛ 인 제산 ·완하용 정제.
- 제 1 항에 있어서, 상기 정제는 산화 마그네슘 입자의 함유 비율이 89 중량% 내지 96 중량% 인 제산 ·완하용 정제.
- 삭제
- 삭제
- 삭제
- 제 1 항에 있어서, 붕괴제로서 크로스카르멜로오스나트륨 또는 카르복시스타치나트륨을 1 내지 3.5 중량% 함유하는 제산 ·완하용 정제.
- 제 1 항에 있어서, 상기 산화 마그네슘 입자를 필요에 따라 결합제, 붕괴제또는 이들 모두와 함께 4 내지 8 ㎫ 의 압력으로 건식 조립된 과립형 산화 마그네슘 입자로 형성된 제산 ·완하용 정제.
- 삭제
- 제 1 항에 있어서, 겉보기 밀도가 0.50 내지 0.70 g/㎖ 인 과립형 산화 마그네슘 입자로 형성된 제산 ·완하용 정제.
- 삭제
- 제 1 항에 있어서, 타정된 후, 정제를 40 ℃ 의 온도이면서 75 % 의 상대 습도 (RH) 조건하에서 6 개월 유지한 경우의 정제는, 그 붕괴 시간의 10 초 이하인 제산 ·완하용 정제.
- 삭제
- 삭제
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JPJP-P-2001-00256421 | 2001-08-27 | ||
| JP2001256421 | 2001-08-27 | ||
| PCT/JP2002/006909 WO2003018034A1 (fr) | 2001-08-27 | 2002-07-08 | Comprimes antiacides et laxatifs |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020087025839A Division KR20080099353A (ko) | 2001-08-27 | 2002-07-08 | 제산 ·완하용 정제 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20040044385A KR20040044385A (ko) | 2004-05-28 |
| KR100972773B1 true KR100972773B1 (ko) | 2010-07-30 |
Family
ID=19084237
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020097009958A Ceased KR20090065552A (ko) | 2001-08-27 | 2002-07-08 | 제산 ·완하용 정제 |
| KR1020087025839A Ceased KR20080099353A (ko) | 2001-08-27 | 2002-07-08 | 제산 ·완하용 정제 |
| KR1020037003649A Expired - Fee Related KR100972773B1 (ko) | 2001-08-27 | 2002-07-08 | 제산 ·완하용 정제 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020097009958A Ceased KR20090065552A (ko) | 2001-08-27 | 2002-07-08 | 제산 ·완하용 정제 |
| KR1020087025839A Ceased KR20080099353A (ko) | 2001-08-27 | 2002-07-08 | 제산 ·완하용 정제 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7147868B2 (ko) |
| EP (1) | EP1421944B1 (ko) |
| KR (3) | KR20090065552A (ko) |
| CN (1) | CN1262278C (ko) |
| AT (1) | ATE380546T1 (ko) |
| AU (1) | AU2002318630B2 (ko) |
| CA (1) | CA2424554C (ko) |
| DE (1) | DE60224056T2 (ko) |
| DK (1) | DK1421944T3 (ko) |
| ES (1) | ES2296960T3 (ko) |
| MX (1) | MXPA03003292A (ko) |
| MY (1) | MY134676A (ko) |
| NO (1) | NO333440B1 (ko) |
| PT (1) | PT1421944E (ko) |
| RU (1) | RU2284189C2 (ko) |
| TW (1) | TWI331044B (ko) |
| WO (1) | WO2003018034A1 (ko) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9720061D0 (en) | 1997-09-19 | 1997-11-19 | Crosfield Joseph & Sons | Metal compounds as phosphate binders |
| US20050220865A1 (en) * | 2004-04-02 | 2005-10-06 | Koleng John J | Compressed composition comprising magnesium salt |
| US20060165759A1 (en) * | 2005-01-27 | 2006-07-27 | Warner-Lambert Company Llc | Antacid lozenge containing micronized particles |
| MY157620A (en) | 2006-01-31 | 2016-06-30 | Cytochroma Dev Inc | A granular material of a solid water-soluble mixed metal compound capable of binding phosphate |
| GB0714670D0 (en) * | 2007-07-27 | 2007-09-05 | Ineos Healthcare Ltd | Use |
| GB0720220D0 (en) * | 2007-10-16 | 2007-11-28 | Ineos Healthcare Ltd | Compound |
| CN101835478B (zh) * | 2007-10-29 | 2012-12-26 | 协和化学工业株式会社 | 缓泻剂 |
| CA2753316A1 (en) * | 2009-02-25 | 2010-09-02 | Kyowa Chemical Industry Co., Ltd. | Magnesium oxide granules |
| SG10201401678TA (en) * | 2009-04-22 | 2014-06-27 | Kyowa Chem Ind Co Ltd | Tablet and pestle therefor |
| GB0913525D0 (en) | 2009-08-03 | 2009-09-16 | Ineos Healthcare Ltd | Method |
| BR112012005163A2 (pt) * | 2009-09-08 | 2016-05-03 | Kyowa Chem Ind Co Ltd | comprimido antiácido e laxante compreendendo partículas de óxido de magnésio, processo para produzir um comprimido antiácido e laxante, e, uso do comprimido |
| GB201001779D0 (en) | 2010-02-04 | 2010-03-24 | Ineos Healthcare Ltd | Composition |
| CN102283861A (zh) * | 2010-06-17 | 2011-12-21 | 杭州赛利药物研究所有限公司 | 氢氧化镁在制药中的用途以及氢氧化镁制剂和制备方法 |
| PL395069A1 (pl) * | 2011-05-31 | 2012-12-03 | Warszawski Uniwersytet Medyczny | Przeciwbólowa kompozycja farmaceutyczna do podawania doustnego |
| JP2014224080A (ja) * | 2013-05-17 | 2014-12-04 | 協和化学工業株式会社 | 大腸の検査または手術のための処置剤 |
| JP6343338B2 (ja) | 2014-02-25 | 2018-06-13 | 神島化学工業株式会社 | 医薬用又は食品添加用酸化マグネシウム顆粒 |
| CN108686222B (zh) * | 2018-06-13 | 2021-03-19 | 合肥合源药业有限公司 | 瑞舒伐他汀钙组合物的制备方法 |
| TWI724629B (zh) * | 2018-11-16 | 2021-04-11 | 日商協和化學工業股份有限公司 | 緩瀉用錠劑 |
| CN111281855B (zh) * | 2020-03-23 | 2021-09-24 | 乐普制药科技有限公司 | 一种雷贝拉唑肠溶片及其制备方法 |
| CN115487160A (zh) * | 2022-09-27 | 2022-12-20 | 威海百合生物技术股份有限公司 | 一种氧化镁片及其制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH674148A5 (ko) * | 1986-06-24 | 1990-05-15 | Racz Istvan | |
| JP2731854B2 (ja) * | 1989-02-10 | 1998-03-25 | 協和化学工業株式会社 | 高耐水和性、高流動性酸化マグネシウムの製造方法 |
| DE3937455A1 (de) * | 1989-11-10 | 1991-05-16 | Nordmark Arzneimittel Gmbh | Antacidatabletten |
| IT1250701B (it) * | 1991-07-24 | 1995-04-21 | Angelini Francesco Ist Ricerca | Composizione farmaceutica solida per uso orale a base di dapiprazolo |
| JP2711614B2 (ja) * | 1992-06-10 | 1998-02-10 | 新日本製鐵株式会社 | 皮膜特性及び磁気特性の優れた方向性電磁鋼板の製造方法 |
| SE9302395D0 (sv) * | 1993-07-09 | 1993-07-09 | Ab Astra | New pharmaceutical formulation |
| JPH0940561A (ja) * | 1995-08-02 | 1997-02-10 | Fujitsukusu Kk | 瀉下剤 |
| JPH10120416A (ja) * | 1996-10-17 | 1998-05-12 | Kyowa Chem Ind Co Ltd | 水懸濁用水酸化マグネシウム粉末 |
| JP2000001428A (ja) * | 1998-04-16 | 2000-01-07 | Nippon Shinyaku Co Ltd | 錠剤及び製造法 |
| RU2189560C2 (ru) * | 1998-08-24 | 2002-09-20 | Товарищество с ограниченной ответственностью "Научно-производственный центр "Квазар-ВВ" | Квазар-способ взрывного разрушения крупногабаритных объектов и квазар-заряды для его осуществления |
| JP2001048792A (ja) * | 1998-11-26 | 2001-02-20 | Fujix Kk | 瀉下剤 |
-
2002
- 2002-07-08 RU RU2003112224/15A patent/RU2284189C2/ru not_active IP Right Cessation
- 2002-07-08 WO PCT/JP2002/006909 patent/WO2003018034A1/ja not_active Ceased
- 2002-07-08 DE DE60224056T patent/DE60224056T2/de not_active Expired - Lifetime
- 2002-07-08 DK DK02745874T patent/DK1421944T3/da active
- 2002-07-08 PT PT02745874T patent/PT1421944E/pt unknown
- 2002-07-08 AT AT02745874T patent/ATE380546T1/de active
- 2002-07-08 AU AU2002318630A patent/AU2002318630B2/en not_active Ceased
- 2002-07-08 EP EP02745874A patent/EP1421944B1/en not_active Expired - Lifetime
- 2002-07-08 CA CA002424554A patent/CA2424554C/en not_active Expired - Fee Related
- 2002-07-08 CN CNB028027949A patent/CN1262278C/zh not_active Expired - Fee Related
- 2002-07-08 KR KR1020097009958A patent/KR20090065552A/ko not_active Ceased
- 2002-07-08 US US10/380,407 patent/US7147868B2/en not_active Expired - Fee Related
- 2002-07-08 KR KR1020087025839A patent/KR20080099353A/ko not_active Ceased
- 2002-07-08 MX MXPA03003292A patent/MXPA03003292A/es active IP Right Grant
- 2002-07-08 KR KR1020037003649A patent/KR100972773B1/ko not_active Expired - Fee Related
- 2002-07-08 ES ES02745874T patent/ES2296960T3/es not_active Expired - Lifetime
- 2002-07-16 TW TW091115825A patent/TWI331044B/zh not_active IP Right Cessation
- 2002-08-26 MY MYPI20023153A patent/MY134676A/en unknown
-
2003
- 2003-04-25 NO NO20031873A patent/NO333440B1/no not_active IP Right Cessation
Non-Patent Citations (2)
| Title |
|---|
| 공개특허 특2000-0035693호 (2000.06.26)* |
| 일본공개특허 특개2000-1428 (2000.01.07)* |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2424554C (en) | 2009-08-18 |
| HK1061641A1 (zh) | 2004-09-30 |
| DK1421944T3 (da) | 2008-03-31 |
| CA2424554A1 (en) | 2003-03-06 |
| NO333440B1 (no) | 2013-06-03 |
| DE60224056T2 (de) | 2008-12-04 |
| CN1262278C (zh) | 2006-07-05 |
| TWI331044B (en) | 2010-10-01 |
| RU2284189C2 (ru) | 2006-09-27 |
| AU2002318630B2 (en) | 2007-05-17 |
| NO20031873D0 (no) | 2003-04-25 |
| WO2003018034A1 (fr) | 2003-03-06 |
| NO20031873L (no) | 2003-04-25 |
| CN1473049A (zh) | 2004-02-04 |
| EP1421944A1 (en) | 2004-05-26 |
| MY134676A (en) | 2007-12-31 |
| KR20080099353A (ko) | 2008-11-12 |
| ATE380546T1 (de) | 2007-12-15 |
| US20040022872A1 (en) | 2004-02-05 |
| ES2296960T3 (es) | 2008-05-01 |
| KR20090065552A (ko) | 2009-06-22 |
| US7147868B2 (en) | 2006-12-12 |
| KR20040044385A (ko) | 2004-05-28 |
| DE60224056D1 (de) | 2008-01-24 |
| MXPA03003292A (es) | 2004-12-13 |
| EP1421944A4 (en) | 2005-08-31 |
| EP1421944B1 (en) | 2007-12-12 |
| PT1421944E (pt) | 2008-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20040044385A (ko) | 제산 ·완하용 정제 | |
| IL165523A (en) | Orally disintegrating tablets with a high dissolution rate along with very good mechanical properties and process for obtaining them | |
| RU2471356C2 (ru) | Декстроза для прямого прессования | |
| PL204141B1 (pl) | Stała postać dawkowa simetikonu do podawania doustnego | |
| RU2501561C1 (ru) | Антацидная и слабительная таблетка | |
| US20140225303A1 (en) | Medicinal compositions quickly disintegrating in the oral cavity and process for producing the same | |
| JP4015485B2 (ja) | 制酸・緩下用錠剤 | |
| KR100571085B1 (ko) | 저치환도 히드록시프로필셀룰로오즈 함유 고형 제제 및그의 제조 방법 | |
| JP2004315483A (ja) | 口腔内崩壊錠剤 | |
| CA2858821A1 (en) | Simethicone formulation | |
| JP2001322927A (ja) | 低置換度ヒドロキシプロピルセルロース含有固形製剤及びその製造方法 | |
| US6274172B1 (en) | Therapeutic effervescent compositions | |
| WO2007018057A1 (ja) | 口腔内速崩壊錠およびその製造法 | |
| EP2575755A2 (en) | Orodispersible tablets of erythritol and isomalt | |
| AU699591B2 (en) | Therapeutic effervescent compositions | |
| JP5160156B2 (ja) | 栄養機能食品錠剤 | |
| JP2001328948A (ja) | 低置換度ヒドロキシプロピルセルロース含有固形製剤及びその製造方法 | |
| JPH05221853A (ja) | 崩壊性良好な生薬類含有造粒物 | |
| JP2006022060A (ja) | 制酸・緩下用水分散液およびそのための錠剤 | |
| Sohail et al. | Formulation and in vitro evaluation of mouth dissolving tablets of levosulpiride | |
| WO2005009395A2 (en) | Cellulosic fiber containing composition | |
| KR20070112043A (ko) | 배뇨장애 치료용 구강 붕해형 정제 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| AMND | Amendment | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| AMND | Amendment | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| J201 | Request for trial against refusal decision | ||
| PJ0201 | Trial against decision of rejection |
St.27 status event code: A-3-3-V10-V11-apl-PJ0201 |
|
| A107 | Divisional application of patent | ||
| AMND | Amendment | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A18-div-PA0104 St.27 status event code: A-0-1-A10-A16-div-PA0104 |
|
| PB0901 | Examination by re-examination before a trial |
St.27 status event code: A-6-3-E10-E12-rex-PB0901 |
|
| B601 | Maintenance of original decision after re-examination before a trial | ||
| PB0601 | Maintenance of original decision after re-examination before a trial |
St.27 status event code: N-3-6-B10-B17-rex-PB0601 |
|
| J301 | Trial decision |
Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20080924 Effective date: 20100526 |
|
| PJ1301 | Trial decision |
St.27 status event code: A-3-3-V10-V15-crt-PJ1301 Decision date: 20100526 Appeal event data comment text: Appeal Kind Category : Appeal against decision to decline refusal, Appeal Ground Text : 2003 7003649 Appeal request date: 20080924 Appellate body name: Patent Examination Board Decision authority category: Office appeal board Decision identifier: 2008101009672 |
|
| PS0901 | Examination by remand of revocation |
St.27 status event code: A-6-3-E10-E12-rex-PS0901 |
|
| S901 | Examination by remand of revocation | ||
| GRNO | Decision to grant (after opposition) | ||
| PS0701 | Decision of registration after remand of revocation |
St.27 status event code: A-3-4-F10-F13-rex-PS0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| FPAY | Annual fee payment |
Payment date: 20130604 Year of fee payment: 4 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 4 |
|
| FPAY | Annual fee payment |
Payment date: 20140530 Year of fee payment: 5 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 5 |
|
| FPAY | Annual fee payment |
Payment date: 20150601 Year of fee payment: 6 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 6 |
|
| FPAY | Annual fee payment |
Payment date: 20160603 Year of fee payment: 7 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 7 |
|
| LAPS | Lapse due to unpaid annual fee | ||
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20170723 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20170723 |